Avenue Biosciences

Avenue Biosciences is a private, pre-revenue platform technology company based in Helsinki, Finland. It has developed a unique AI-powered platform focused on engineering signal peptides to boost the expression and quality of therapeutic proteins in mammalian production systems, claiming yield improvements of up to 500%. The company, which raised $5.7M in early 2026, aims to serve as a critical tools and services provider to biopharma companies, helping to de-risk and accelerate the development of protein-based therapeutics. Its technology originated from research at the University of Helsinki.

AI-powered protein engineering platform focused on optimizing N-terminal signal peptides. It combines high-throughput synthetic biology, chemistry, and machine learning to analyze thousands of sequences and identify variants that dramatically boost secretion yield and quality of therapeutic proteins in mammalian production systems.

Avenue competes with other protein engineering and cell line development companies (e.g., ATUM, Twist Bioscience's expression optimization services) and the internal development teams of large biopharma firms and CDMOs. Its unique focus on high-throughput signal peptide engineering using a proprietary AI/ML approach is its key differentiator in a crowded tools market.